Xieli Biotechnology

Sichuan Xieli Pharmaceutical is a prominent Chinese pharmaceutical enterprise specializing in the research, development, and large-scale production of plant-derived active pharmaceutical ingredients (APIs). Established in 1982, the company is a global leader in the production of flavonoids, including Rutin, Quercetin, and Troxerutin, as well as high-potency oncology agents like Paclitaxel and Docetaxel. Xieli operates multiple GMP-certified manufacturing facilities and provides contract development and manufacturing services (CDMO) to international pharmaceutical partners. Their business model integrates sustainable raw material sourcing with advanced extraction and synthesis technologies to serve the oncology and cardiovascular healthcare sectors.